A sensitive and rugged gas chromatographic-mass spectrometric (GC-MS) method was developed for determining 11 polycyclic aromatic hydrocarbons (PAHs) in 4-g specimens of human lung, breast, and liver tissue. The precision of the method was determined from duplicate analyses of specimens (16-38%RSD) and from duplicate GC-MS analysis of tissue extracts (8) (9)(10)(11)(12)(13)(14)(15)(16)(17). Benzo[a]pyrene was detected at measurable levels in 87% of the lung specimens. This method makes possible the measurement of ambient levels of PAHs in small samples of human tissue such as those obtained by biopsy.
Introduction
Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous environmental contaminants, formed principally during combustion of fossil fuels. Runoff from contaminated soil in industrial areas has produced polluted rivers and lakes, leading to bioaccumulation through plankton, molluscs, and fish (1) . Human exposure to PAHs is, to a great extent, from the ingestion of foodstuffs grown in contaminated soil or prepared by charcoal-broiling or smoke curing (2) . In a study of residents living near a suspected industrial source of PAHs, benzo [a] pyrene (BaP) uptake from the ingestion of contaminated food has been reported as 20-800 ng/day (3) . Tobacco * Author to whom t orrespondence should be addressed smoke, on the other hand, is a the primary source of PAHbearing particulates indoors and, among smokers, is the primary cause of lung cancer (4) . Researchers have reported BaP concentrations in restaurants and public places in the range of 2.8 to 760 ng/m g and have reported BaP levels in mainstream tobacco smoke at 20 to 40 ng/cigarette (4) .
Whether exposure is to active or passive cigarette smoke or to industrial sources, an estimate of the body burden of PAHs is necessary to establish an association between exposure and adverse health effects. A method has been reported for the determination of PAHs in 364 formalin-fixed lung specimens obtained from autopsy using large (50 g) sample quantities (5) . Mean concentrations of benzo[a]pyrene, benzo[k]fluoranthene, and benzo[ghi]perylene were reported as 0.54, 0.44, and 0.87 ng/g, respectively, by dry weight basis. The researchers reported levels as low as 0.1 ng/g (dry weight basis) using highperformance liquid chromatography (HPLC) with fluorescence detection. PAHs in mussels were measured by gas chromatographymass spectrometry (GC-MS) following saponification, extraction with pentane, partitioning the extract with DMSO, and Florisil microcolumn cleanup (6) . Concentrations for 12 PAHs from homogenized mussel tissue were reported in the range of 4.4 to 155 ng/g. The researchers discussed the presence of squalene and other unsaturated compounds in the extracts following purification and the rather high level (19 ng) of phenanthrene in their method blanks.
Others reported a GC method to determine PAHs in fish tissue in which they saponified the tissue, acidified the digestare, and extracted the PAHs with cyclopentane/dichloromethane (7) . The extract was purified for PAHs using adsorption chromatography followed by gel permeation chromatography. They reported a method limit of quantitation (MQL) of 20 ng/g and indicated that the extract residue after cleanup contained high levels of squalene.
A group at the U.S. FDA reported a method for determining PAHs in seafood using saponification, partition into trichlorotrifluoroethane, purification on solid-phase extraction (SPE) cartridges, and analysis by HPLC with fluorescence detection (8) .
The investigators reported good recovery from seafood fortified in the range of about 1.5 to 3 ppb. Although the HPLC-fluorescence instrumentation is very sensitive, it does not have the mass selectivity of GC-MS-SIM, and it only provides weak confirmational data. This paper reports a method for determining PAHs in 4-g specimens of unfixed, frozen human lung, breast, and liver tissue at concentrations from 0.01 to 1.2 ng/g and presents quality-control information for the analysis of 200 human tissue specimens extracted and analyzed over a 25-week period. QC information that demonstrates the method to be sensitive and rugged for the analysis of lung and other tissues for PAHs down to 0.01 ng/g is presented.
Experimental

Reagents and solvents
Acetone, hexane, dichloromethane (DCM), and iso-octane were acquired in GC grade from Burdick and Jackson (Muskegon, MI). Ethanol (HPLC grade) was obtained from Spectrum Chemical Mfg. (New Brunswick, NJ). Potassium hydroxide pellets, sodium sulfate (Tracepur, 10-60 mesh), and alumina (chromatographic grade, 80-200 mesh, not activated) were obtained from EM Science (Gibbstown N J). Azulene (99%) was obtained from Aldrich Chemical (Milwaukee, WI). Sodium sulfate was precleaned by heating it in an oven at 450~ in a shallow glass tray for 4 h. The alumina was cleaned before use by extraction with DCM followed by hexane, then dried and activated by packing the wet sorbent in a large chromatography column. Purified nitrogen was passed through the column at 400 mL/min. By applying current to a heating tape wrapped around the column, the alumina was slowly heated for 1 h to a final temperature of 115~ then held at this temperature for 1 h. The alumina was poured while hot into an Erlenmeyer flask and sealed with a glass stopper. Aluminum oxide boiling chips, 8-14 mesh, were obtained from Thomas Scientific (Swedesboro, NJ) and extracted and dried before use by the same procedure used for alumina.
Standards
A solution containing 16 PAHs at 2.0 mg/mL in CH2Cl2/benzene (1:1) was obtained from AccuStandard Inc. (New Haven, CT). A standard solution of benzo[e]pyrene at 50 IJg/mL, also obtained from AccuStandard, was combined with the mixed standard to produce a secondary solution containing all of the native analytes at a nominal level of 10 ng/IJL. The surrogate analytes, pyrene-d10, chrysene-d]2, and benzo[e]pyrene-d]2, were obtained neat from Cambridge Isotope Laboratories (Andover, MA). Stock solutions were prepared from these at about 1 mg/mL in toluene; aliquots of the stock solutions were combined and diluted to 10 ng/lJL, and finally diluted to make a sample spiking solution of 0.1 ng/lJL in isooctane. The quantitation standard solution (0.1 ng/tJL) used for spiking purposes was prepared likewise from neat perylene-d12 (AccuStandard), neat 9,10-dichloroanthracene, and 1,2,3,4-tetrachloronaphthalene (both from Ultra Scientific, North Kingstown, RI). Calibration solutions were prepared in isooctane to contain native analytes and surrogates at concentrations ranging from 0.5 to 50 pg/IJL, with the quantitation compounds at a fixed concentration of 10 pg/IaL. A standard reference solution, SRM-1491, was obtained from the National Institute of Standards and Technology (NIST, Gaithersburg, VA). Quantitation standards were added to an aliquot of this solution and diluted to contain most of the PAH analytes at a concentration range of about 2 to 4 pg/IJL.
Specimens
A total of 201 fresh, frozen, human tissue specimens from the National Cancer Institute (NCI) was received in 50-mL polypropylene centrifuge tubes packed on dry ice. The tissues specimens' weights ranged from 1.4 to 13 g with the median at 5.3 g. The tissues were stored at < -70~ until just before analysis. The specimens had been obtained from patients undergoing surgery. The patient histories were kept confidential and unknown to laboratory personnel. Among the 201 samples were 90 lung, 68 breast, and 43 liver specimens. One of the lung extracts was lost during laboratory workup.
Analytical procedure
The described laboratory analytical procedure is depicted in Figure 1 . Under yellow lights (General Electric Gold F40GO fluorescent tubes), 4 g of tissue was weighed into a boiling flask and 25 mL ethanol added. Ten microliters (1 ng/compound) of the surrogate compounds was added to the flask. Boiling chips were added, the flask was connected to the reflux condenser, and the ethanol was quickly heated to a boil. Potassium hydroxide pellets (2 g) were added to the flask through the top of the condenser, and the condenser was then covered with clean aluminum foil. (Air, in combination with KOH and acetone, an impurity in ethanol, was thought to cause the yellowing of the reflux solution, producing a high background signal during GC-MS analysis.) The digestion was allowed to continue for 2 h, or longer if required to complete the tissue digestion. The digest was allowed to cool, then decanted to a separatory funnel with two successive rinses of 4 mL of ethanol, followed by two successive rinses of 7.5 mL of hexane. The separatory funnel was shaken vigorously for 1 rain, then let sit for 30 rain. The aqueous phase was drained into a beaker with any remaining emulsion. The hexane phase was collected in a small culture tube. The aqueous phase was transferred back to the separatory funnel with two 5-mL rinses of hexane and re-extracted as before. The second hexane extract was combined with the first.
To avoid the formation of an intractable emulsion in the following aqueous extraction (backwash) step, the culture tube containing the hexane extracts was capped and allowed to sit overnight at 4~ The hexane layer was then carefully transferred to a large (75 mL) culture tube using a Pasteur pipet, leaving behind all of the aqueous phase and solids. Twenty milliliters of reagent water was added to the large culture tube. The tube was capped and shaken vigorously for 1 min, then allowed to settle until a complete separation was achieved. Usually this was accomplished within 1 h, but occasionally additional steps were required to break up an emulsion. In such cases, the emulsion was collected in a separate tube and shaken with 5 g sodium sulfate. The hexane phase was then removed and re-extracted with water. The aqueous phase in each step was discarded.
After the aqueous wash, the combined hexane extracts were dried with 5 g sodium sulfate in a clean culture tube, shaking occasionally over a period of 1 h. The dried extract was transferred to a Kuderna-Danish concentrator tube with two 2-mL hexane rinses of the sodium sulfate. The extract was concentrated to about 1 mL using a modified micro Snyder column, one or two boiling chips, and a water bath at about 85~ The concentrated extracts were then partitioned on an activated alumina column to remove co-extractives that may interfere with GC-MS analysis.
A 5-g alumina column was prepared immediately before use. A 10-mL disposable glass column was partially immersed in DCM and packed by adding dry packing materials to the top of the column and allowing them to settle in the solvent. The column was packed with (from bottom to top) a small glasswool plug, 1 g sodium sulfate, 5.0 g activated alumna, and another 1 g sodium sulfate. Without exposing the top of the column bed to air, the column was removed from the DCM in which it was packed and prerinsed with 25 mL DCM followed by 25 mL of a solution of 0.02% (v/v) methanol in hexane. The extract was transferred to the top of the column with a Pasteur pipet. The column was eluted with 25 mL hexane containing 0.02% methanol. This fraction, containing saturated and unsaturated hydrocarbons, was discarded. With a clean concentrator tube under the tip of the column, the PAH fraction was eluted with 25 mL of a solution containing 60% DCM and 0.02% methanol in hexane.
The eluate was concentrated to 0.5 mL using a modified micro Snyder column and a warm water bath. The Snyder column was rinsed down with 1 mL of iso-octane. Ten micro-liters of the quantitation standards solution (1 ng/compound) was added, and the extract was mixed and transferred to a 2-mL conical vial for final concentration to about 100 IJL using a heating block and a gentle stream of nitrogen. The final extract was carefully mixed using a Pasteur pipet and transferred to a 200-tJL insert inside an autosampler vial. The vial was capped and stored in a jar at 4~ for up to 30 days before GC-MS analysis.
GC-MS analysis
Capillary GC analysis was performed on a Hewlett-Packard 6890 GC using a Restek Rtx-5MS 5% diphenyldimethylpolysiloxane column (60 m x 0.25-ram i.d., 0.1-1Jm phase thickness). Instrumental conditions used included injector and transfer line temperatures of 300~ helium inlet pressures of 40 psi, and a 1-1JL injection using a splitless injection time of 1.0 min. The column temperature program was 100~ (no hold) to 130~ at 15~ then 8.0~ to 300~ with a 20-min final hold using a constant flow mode at 1.1 mL/min. Positive ion (70 eV) mass spectral data were collected on a Hewlett-Packard 5973 MS operating in the selected ion monitoring mode. The MS was tuned for 70 eV electron ionization to meet factory specifications using perfluorobutylamine (FC-143). All data were processed using the Hewlett-Packard ChemStation data system. Peak areas were measured for two or more ions per analyte.
Quality control
To ensure that the purification step and recovery of PAHs were achieved at a consistent level, the activity of the alumina was monitored by measuring the volume of hexane required to elute azulene (1 mg dissolved in 1 mL hexane) from a 5-g column prepared as described. We achieved optimal PAH recovery and reduction of co-extractives with alumina columns on which azulene eluted in a band starting at 35 mL and tailing off at 55 mL. When azulene was retained beyond 65 mL or started eluting before 30 mL, a new batch of alumina was prepared and tested before use in tissue analysis.
The concentrations of native and deuterated PAHs and surrogate compounds were computed using internal standard calculations. Eight calibration solutions spanning a range of analyte concentrations from 0.5 to 50 pg/IJL were analyzed by GC-MS, monitoring at least two ions per analyte. Each solution contained the quantitation standards at 10 pg/tJL. The response ratios (analyte ion/quantitation ion) were plotted versus the concentration ratios, and a quadratic curve was fitted by the least-squares method. The calibration of the instrument was acceptable over the range of calibration standards in which the measured concentration of an analyte fell within 25% of the nominal value. A 2-pg/IJL calibration standard was analyzed as a calibration check before starting the analysis of a batch of samples and between groups of no more than five samples. The check standard was acceptable if the calculated concentrations of every analyte was within 25% of the known value. Extract analyses were acceptable only when bracketed by acceptable check standards. For quality-control purposes, the sensitivity of the analytical system was determined before and after the analysis of each group of 10 samples by analyzing a calibration stan-
Tissue samples were analyzed in batches of 10, including 1 duplicate tissue specimen. Over the course of analyzing 200 samples, 11 tissue specimens were analyzed in duplicate, 1 aliquot fortified with 1 ng of each analyte, the other unfortified. Ten specimens were also analyzed in duplicate without fortification of either aliquot. A method blank (a reagent blank, carried through the entire procedure) and a method control (a reagent blank fortified with 0.2 ng of each analyte) were in- cluded in each batch that was prepared. In addition to the duplicate tissue aliquots, one tissue extract in each batch was analyzed twice by GC-MS.
* Concentration given in ng/g, assuming a tissue mass of 4 g; SD = standard deviation; n/d = not detected. t Number of method blanks where analyte concentration > LOQ (0.01 ng/g). r Method controls were spiked with 0.2 ng PAHs = 0.050 ng/g (assuming a 4-g sample).
Tissue spiked at 0.25 ng/g, tissue background values were subtracted. " Mean and SD given for (RTI analysis of SRM/values provided by NIST x 100).
Results and Discussion
QC results
Method validation was conducted before proceeding with the analysis of human tissue specimens. Three method blanks and six method controls were prepared and analyzed. Three of the method controls were fortified with 1 ng of each PAH (0.25 ng/g, assuming a sample size of 4 g); the other three were fortified with 0.2 ng (0.05 ng/g). The resuits of this method validation are given in Table I . No background was detected in the method blanks for 9 of the 11 PAHs. The background for fluoranthene and pyrene was very low. The recoveries and precision were excellent at both fortification levels. Twenty-two method blanks were analyzed over the course of the study. Table II gives the average and standard deviation of levels found in the blanks and the frequency with which analytes exceeded the instrumental limits of quantitation (LOQ). The accuracy of this method was determined by the extraction of fortified tissue aliquots, by the processing of method controis, and by analysis of a dilution of an NIST standard reference solution, SRM-1491. A summary of the data from these tests is also presented in Table II curacy of duplicate tissue extractions is confounded by the inhomogeneous nature of the tissue and the difficulty of obtaining a representative aliquot of sample. In most cases, tissue duplicates were made by cutting one contiguous specimen into two using surgical scissors. The results obtained from duplicate GC-MS analyses, on the other hand, give a fair representation of the difficulties resulting from low-picogram measurements over the considerable background of co-extractives. Nevertheless, the results indicated excellent precision for instrumental measurement and for the method as a whole. Surrogate recovery was one of the most useful measures of method performance employed in this study. Three surrogate compounds in this study were used to assist in evaluating the quality of the data produced with each sample analysis. The QC criterion of acceptability for recovery of surrogate compounds was set to limits of 70 to 120%. Over the course of analyzing these 200 samples, the percent of samples that met this criterion were 68% for pyrene-dl0, 88% for chrysene-d12, and 81% for benzo[e]pyrene-d12. Approximately 64% of all tissue analyses met the QC criterion for two or more surrogate compounds, whereas 75% of the lung analyses met the criterion for two or more surrogates. All samples were fortified with ] ng of the surrogate compounds.
Detection limit
The greatest advantage this method presents over methods reported previously is the combination of a low MQL and the use of a fairly small (4 g) sample size. Previous methods have taken advantage of HPLC with fluorescence detection to achieve low MQLs, but with poor resolution of PAH isomers and no means of confirmation. With the advent of the current generation of quadrupole mass spectrometers, the sensitivity of the fluorescence detector can be surpassed with the advantage of the greater resolving power of capillary GC and the mass selectivity of MS with confirmation using multiple ion monitoring. However, GC-MS requires a cleaner extract than does HPLC in order to avoid excessive instrument maintenance and matrix-induced bias. We have developed a method that reduces the co-extractives to a level that permits the GC-MS analysis of 50 or more extracts before GC inlet service is required and permits at least 300 extract analyses before GC column replacement is required. The resulting MQL makes this method applicable to human tissues; the small sample size used in this method permits PAH determination in studies where only a small amount of tissue is available. We anticipate that this method could be used to analyze human biopsy specimens and whole organs of small laboratory animals.
The MQL was defined as three times the analyte level measured in the method blank; when no analyte was detected in the method blank, the MQL was calculated from the GC-MS limit of quantitation (LOQ). The LOQ was defined as the lowest acceptable calibration level (analytes within 25% of nominal values.) Depending on the anaIyte, the LOQ was either 0.5 or 0.75 pg/pI,. Assuming a clean method blank, a sample mass of 4 g, and a final extract volume of 0.1 mL, we calculate an MQL in tissue of 0.01 to 0.02 ng/g. The purification procedures used in this study proved to be effective in reducing co-extractives to a level that permitted quantitation of PAHs in most samples down to 0.01 ng/g. A greater impediment to method detection limit was the detection of low levels of four-ring PAHs in nearly a fifth of the method blanks run. Table II gives the frequency of detection (> 0.01 ng/g) of these compounds in the method blanks and the range of values observed. The detection of a compound in a method blank raises the MQL for the samples in the associated sample batch. Sample values above three times the level found in the method blank were deemed acceptable. By applying this criterion, the average MQLs for the four-ring compounds were as follows: fluoranthene, 0.05 ng/g; pyrene, 0.07 ng/g; benzo[a]anthracene, 0.03 ng/g; and chrysene, 0.03 ng/g. Because five-or six-ring compounds were not detected in any of the method blanks, the MQL for those compounds was limited by the instrumental LOQ to 0.01 to 0.02 ng/g, assuming a sample size of 4 g.
The 200 tissue specimens were analyzed over a period of 25 weeks. Table IV gives the percent of measurable values divided into four categories: (1) not detected; (2) detected, but at a level less than three times the method blank; (3) quantitated at a level at least three times the level (if detected) in the method blank; and (4) specimens. Table V presents the distribution of measurable values for the lung analyses. Benzo[a]pyrene was quantified in 87% of the lung samples. In only a small percentage of lung specimens did co-extractives prevent the determination of three compounds: fluoranthene (2%), pyrene (1%), and indeno(1,2,3-cd)pyrene (1%). Figure 2 is a reconstructed ion chromatogram of a typical lung extract. Analyte concentrations in this specimen ranged from 0.01 to 0.1 ng/g. The cluster of large peaks that elute between 22 and 25 min was typical of all of the tissue analyses. A full-scan MS analysis of this region identified numerous unsaturated hydrocarbons, inc]uding squatene and smaller terpenes.
Ruggedness
This method uses adsorption chromatography to remove interfering co-extractives from the tissue extracts before GC analysis. A 5-g column of basic alumina was chosen on the basis of the capacity of the column to retain co-extractives without breakthrough or compromise of the characteristics of the adsorptive column. Some of the higher molecular weight PAHs were found to be retained by this system using a hexane/DCM mobile phase. Adding a small amount of methanol to the mobile phase facilitated the recovery of benzo[k]fluoranthene, dibenzo{a,h]anthracene, and benzo[ghi]perylene. These compounds will eventually elute in pure DCM; however, co-extracted pigments are not separated from the higher molecular weight PAHs. Changes in the activity of the alumina columns was found to significantly affect method performance. Excessive alumina activity will yield lower recovery of benzo[k]fluoranthene and dibenz[a,h]anthracene, and a too-low activity leads to a breakthrough of pigments and fats. Optimal alumina activity was achieved by adjusting the temperature on the alumina drying column (endpoint: ] 15~ the nitrogen flow rate (400 mL/min), and the drying time (2 h). During the analysis of tissue extracts, coextractives accumulated on the surfaces of the GC inlet, causing an increase in response to PAHs. We suspect that the increase in response is due to the "priming" of the inlet liner by covering active sites with high molecular weight co-extractives. Subsequent recalibra-[[ tion with a set of standard solutions caused stripping the residue from the inlet liner and thereby exposing adsorption sites on the liner surface. A system calibrated with a clean inlet liner would fall out of calibration after ana-~ lyzing only 5 or 10 tissue extracts. To circumvent this problem, we conditioned a new liner by making three injections of a tissue extract. We then calibrated the system by injecting a tissue extract after every two injections of calibration solutions. It was extremely important that the analytical method maintain acceptable performance over the course of the half year required to analyze the specimens and associated qualitycontrol samples. Figures 3 and 4 are plots of two indicators of method performance plotted over the course of sample analysis. Figure 3 presents the results for the analysis of 22 method controls, all fortified with 0.2 ng of each PAH, plotted as percent recovery versus duration (in weeks) of sample analysis. Three compounds are displayed, chrysene, benzo[a]pyrene, and benzo[ghi]perylene, representing four-, five-, and six-ring compounds, respectively. Results show fairly consistent and acceptable recovery over the course of the work. An occasional large positive bias for chrysene is typical of the four-ring compounds and may be due to reagent background. Method controls in only 4 of the 22 analysis batches were outside the quality-control guidelines for recovery. Figure 4 presents the recovery of the surrogate compound benzo[e]pyrene-d12 for all 200 samples, again plotted over the duration of the work. The variation in recovery within a batch (aligned vertically in the figure) is nearly equal to the variation over the duration of the study. Differences in surrogate recovery were noticed between the matrices, with breast tissue yielding lower recoveries than lung tissue. Overall, this analytical method performed better for lung tissue than for the other tissues. This method was optimized using human lung tissue provided by NCI. During the aqueous rinse step, the hexane lung extracts were not as prone to form emulsions. The result was a lower level of co-extractives in the final extract, producing fewer instances of interfering peaks during quantitation, as shown by better agreement between PAH levels calculated from primary versus secondary analyte ions. The saponification step was better for lung than for breast or liver tissues. Lung tissue was digested quickly and completely, whereas the breast tissue occasionally left an oily (unsaponified) layer, and the liver specimens sometimes left about 10% of the tissue intact after 2 h in boiling ethanolic KOH.
